HomeCompaniesProfile

Macromoltek

Computational antibody design 


Company Size

11 - 50 employees

Year Founded

2010


About Macromoltek

Macromoltek: Revolutionizing antibody design.

Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.

Founders & Key People

Monica Berrondo

Monica Berrondo

Founder/CEO, Macromoltek

Susana Kaufmann

Susana Kaufmann

Co-founder of Macromoltek

Share This Profile

More Companies

Turing College

AI-driven online tech school for busy professionals

Bloom

Investing app that teaches you how to invest

Mason

Mason is the fastest way to take smart devices from idea to end user

Axoni

Axoni is building the next generation of capital markets technology

Just Appraised

Just Appraised makes software for local governments.

Canary Technologies

Modernizing the hospitality tech stack.

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2026 BEAMSTART. All Rights Reserved.